Business Wire

Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
presented by
H
More Tools & Gadgets
F&G: 52
6.238,88 S&P · 19,83 Vola-Index · 113.723,51 BTC · 1,15862 EURUSD
Systemstatus: 54.533 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US88023B1035
Letzte Aktualisierung: 03.08.2025 | 6AM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG01MZQYJF9
TEM
Tempus AI, Inc.
GICS: - · Sektor: EQTY · Sub-Sektor: -
NAME
Tempus AI, Inc.
ISIN
US88023B1035
TICKER
TEM
MIC
XNAS
REUTERS
TEM.OQ
BLOOMBERG
TEM US
Fr., 18.04.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in e...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Sa., 29.03.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presen...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mi., 26.03.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025. Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A ...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Silent Ad
Di., 11.03.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies. Deep 6 AI enables healthcare organizations to de-risk clinical trials, ...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mo., 24.02.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024. Year-over-year revenue growth accelerated to 35.8% in the fourth quarter of 2024 Gross profit growth accelerated to 49.7% in the four...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mi., 19.02.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA. Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Monday, March 3...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Di., 18.02.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Do., 13.02.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patie...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Di., 11.02.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company’s quarterly earnings will be released the same day. T...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mo., 03.02.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. “This acquisition com...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Silent Ad
Di., 21.01.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI t...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mi., 15.01.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved tes...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Di., 14.01.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant. Tempus One, which initially launched in 2023, provides both physicians and researchers AI-enabled...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mo., 13.01.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Select, Preliminary, Unaudited Financial Results Revenue of approximately $693 millio...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Di., 07.01.2025       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the 43rd Annual J.P. Morgan Healthcare on January 13-16, 2025, in San Francisco, CA. Company Presentation | Tempus Founder and CEO, Eric Lefkofsky, will deliver a presentation and host a Q&A with...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mi., 18.12.2024       Tempus AI
US88023B1035

Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the company has signed agreements for in-network provider status with Blue Cross Blue Shield (BCBS) of Illinois, Blue Shield of California, and Avalon Healthcare Solutions, a laboratory benefit manager. As part of the agreem...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Di., 17.12.2024       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the impact of a new decision by the Centers for Medicare and Medicaid Services (CMS) that will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm. ECG-AF is one of ...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mo., 25.11.2024       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, held in New York, New York. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the c...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Di., 12.11.2024       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly ...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Mo., 11.11.2024       Tempus AI
US88023B1035

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospec...
weiterlesen
Tempus AI
Research & Analysen Termsheet Terminal
Permalink
Silent Ad

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.

Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S